49
Participants
Start Date
August 31, 2005
Primary Completion Date
March 31, 2009
Study Completion Date
March 31, 2014
Gleevec
Imatinib-400mg po qd for 10 days to commence on day 3. On day 0, Docetaxel 60mg/m\^2 administered IV
Docetaxel
60 mg/m\^2 administered IV on day 0
Hillman Cancer Center, Pittsburgh
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
Leonard Appleman
OTHER